252367-34-3Relevant articles and documents
Synthesis of 2-arylhydrazono-4-chloro-3-oxobutanoates existing as (E)/(Z)-hydrazone isomers in solution: Correlation between equilibrium constants and substituent constants
Kawamura, Chihaya,Yoshida, Kiminari,Yamazaki, Naoki,Sato, Noriko,Nagai, Kenichiro,Kaji, Eisuke,Kurasawa, Yoshihisa
, (2020)
Various 2-arylhydrazono-4-chloro-3-oxobutanoates 10a-i synthesized by the reaction of ethyl 4-chloro-3-oxobutanoate with the 4-substituted benzenediazonium chlorides were found to exist as two isomers between the (E)- and (Z)-hydrazone forms in DMSO?dsub
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL)
Breinbauer, Rolf,Doler, Carina,Fuchs, Elisabeth,Grabner, Gernot F.,Mayer, Nicole,Melcher, Michaela-Christina,Migglautsch, Anna K.,Romauch, Matthias,Schweiger, Martina,Zechner, Rudolf,Zimmermann, Robert
supporting information, (2020/07/13)
High serum fatty acid (FA) levels are causally linked to the development of insulin resistance, which eventually progresses to type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin resistance and NAFLD. In this article, we report about structure–activity relationship (SAR) studies of small molecule inhibitors of murine ATGL which led to the development of Atglistatin. Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target.